• Appropriate at least $472.4 million in FY 2024 appropriations for the CDC Division of Cancer Prevention to support comprehensive cancer control, central cancer registries, and screening and awareness programs for specific cancers. • Allocate $50 million in funding for the Oncology Center of Excellence at FDA in FY 2024 to provide regulators with the capable staff and necessary tools to conduct expedited review of cancer-related medical products. In summary, if we are to achieve the Cancer Moonshot goal of ending cancer as we know it, it will require robust funding for NIH and NCI biomedical research programs, as well as significant budget increases for FDA and CDC. If Congress follows through on these recommendations, we will improve our nation’s health, including the lives of patients with cancer, and sustain our leadership in cancer research and medical science. Scan the QR code to watch a video summary of the report Executive Summary AACR Cancer Progress Report 2023 9
RkJQdWJsaXNoZXIy NTkzMzk=